Medicus Pharma Ltd. Common Stock (MDCX)
MDCX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MDCX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001997296 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | ON |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "This uncertainty, together with the Company's continued losses and outstanding debt obligations, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-11-06 |
| Cash and burn | $5.0M cash; operating cash flow -$9.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,922,837 (2026-11-02); 22,029,144 a year earlier. 1y figure adjusted for split (1-for-50 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-10-12 | Source 2026-10-12 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-02 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-10-23 |
| Auditor | KPMG LLP, New York, New York, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$15.2M | -$15.9M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$11.6M | -$7.0M | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$9.0M | -$9.0M | $6.4M | $2.3M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$15.1M | -$6.6M | $8.7M | $5.2M | Needs four quarters | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | Not filed | -$20.9M | -$6.8M | $8.7M | $6.8M | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$6.2M | -$5.5M | $9.7M | $4.7M | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$5.1M | -$3.9M | $4.0M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$3.5M | -$3.2M | $4.2M | $0 | Needs four quarters | 10-K 2026-03-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B3 | 424B3 | 2026-11-16 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-29 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-06 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-10-30 |
Source: SEC EDGAR submissions feed, 350 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.3% |
| 1 month | -40.5% |
| 3 months | -89.0% |
| Year to date | -97.5% |
| 1 year | -98.3% |
| From 52-week high | -98.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| MDCXW | Medicus Pharma Ltd. Warrant | $0.2000 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier